# Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Source: https://onco.cc/trials/nct06777433/  
OnCo record `nct06777433` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of RAD101 (18F-FPIA) in brain and spinal cord tumours, run by Radiopharm Theranostics, Ltd, active and no longer recruiting.

## Summary

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases is a phase 2 interventional study registered as NCT06777433 by Radiopharm Theranostics, Ltd, with 30 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-04-23. Interventions recorded: RAD101 (18F-FPIA).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06777433
- Phase: 2
- Setting: An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants With Suspected Recurrent Brain Metastases From Solid Tumors
- Sponsor: Radiopharm Theranostics, Ltd
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06777433: https://clinicaltrials.gov/study/NCT06777433

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- companies: [Medpace](https://onco.cc/companies/medpace/)

---
JSON: https://onco.cc/api/v1/entities/nct06777433.json